Hi Shu, can you confirm if the $4M valuation cap are early bird terms?

Hi Francis! Thanks for reaching out. Yes I can confirm for the first 100k early-bird investments, the cap is 4M. Please feel free to send email to shu@petribio.com if you have more questions!

And is there a discount rate attached to the standard terms?

Hi Francis, there's no discount rate to the standard terms, but the early bird term has a lower cap value (4M). Also, for investors we know or put in above a certain threshold, we can potentially negotiate or even waive the fee. In addition, investing with IRA is also an option. If you want to know more, feel free to send an email to me!

Hi, What's the goal 6 months from now? Who am I investing in when I invest in Shu Li?

6 months from now we will get more lab-based proof of concepts to show the effectiveness of peptides. For each peptide proved to be useful for an application (therapeutic function, metabolism regulation, etc), we will file a patent to protect the intellectual properties as well. I truly appreciate everyone that interested in our project and want to know more about us. Please feel free to send me an email at shu@petribio.com, and I'd love to schedule a zoom meeting to let you know more about o...

IS the 32+ terabytes of genomic data proprietary? or is the advantage you have is that you've found a better way to mine it?

Hey Glen, great question. The 32 Tb of data is from the Human Microbiome Project, it was generated with public funding and is publicly available. We get the benefit of mining it without having to reinvent the wheel in terms of massive data collection. Our edge is in how we analyze this data for potentially useful gene sequences, expressing them for the first time in a laboratory setting, testing them, and developing IP around specific use cases for them. Hope this helps! -Joe

You answered other questions, are you avoiding mine?

Hi Leonardo, we are so sorry for missing your question. For some reason we just can't see it on our end. I apologize for the inconvenience. Would you mind re-posting your question here? Happy to answer it!

Petri Bio Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

We develop therapeutics inspired by the data collected by animal and microbial genome projects.

Positioned to mine 32+ terabytes of genomic data for future drug precursors.

Founded by 2 PhD scientists (3 patents and 14 publications). 2nd-time founder (YCS17).

Patent-pending treatment for COVID-19 under evaluation by a pharma company for sponsorship.

Early pipeline of candidates help treat IBD, which affects 1.6M people and $15B market

Drug precursor for the treatment of NAFLD/NASH (“fatty liver disease”), $7B growing market.

Petri Bio

Next-generation of therapeutics from gut microbes

$107,683

Petri Bio

Quick facts

Team profiles

Featured investor profiles

$107,683

Ask